Sionna Therapeutics, Inc. (SION) Price & Analysis

Compare

18 Followers

SION Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.26 - $30.61

Previous CloseN/A

VolumeN/A

Average Volume (3M)282.20K

Market Cap

$1.26B

Enterprise Value$512.36M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.06

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding44,139,824

10 Day Avg. Volume344,004

30 Day Avg. Volume282,200

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$37.67

Price Target Upside28.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical SuperioritySION has demonstrated in vitro superiority of its cystic fibrosis assets compared to Vertex's Trikafta.

Innovation And ExpertiseSionna Therapeutics is advancing novel cystic fibrosis drugs, with its co-founders developing two NBD1 stabilizers, SION-451 & SION-719, that are likely superior to the standard of care Trikafta.

Market PotentialPatients not on Trikafta due to intolerance or poor response are likelier to start on a novel drug, providing a potential market for SION's products.

Bears Say

Clinical Performance UncertaintyIf a drug has poor lung bioavailability or patient's baseline disease is too advanced, it could perform less optimally in clinic than predicted by the assay.

Market Penetration ChallengePatients stable on Trikafta are unlikely to be switched to a new drug, limiting the potential market for SION's new products.

Sionna Therapeutics, Inc. News

Sionna Therapeutics appoints Caroline Stark Beer as CBO

Sionna Therapeutics (SION) announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer. She was...

26d ago

SION

Sionna Therapeutics initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $46 price target Sionna is clinical...

26d ago

SION

Short Report: Frontier Group short positioning continues gaining altitude

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

27d ago

GRND

Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials

Sionna Therapeutics, Inc. (SION) has received a new Buy rating, initiated by JonesTrading analyst, Debanjana Chatterjee. Debanjana Chatterjee...

26d ago

SION

Sionna Therapeutics initiated with a Sector Perform at RBC Capital

RBC Capital analyst Brian Abrahams initiated coverage of Sionna Therapeutics (SION) with a Sector Perform rating and $22...

1M ago

SION

Sionna Therapeutics initiated with a Strong Buy at Raymond James

Raymond James initiated coverage of Sionna Therapeutics (SION) with a Strong Buy rating and $45 price target. Sionna...

1M ago

SION

VRTX

Short Report: C3.AI short positioning at 2025-high

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

1M ago

TEM

Sionna Therapeutics announces first subjects dosed in Phase 1 trial on SION-451

Sionna Therapeutics (SION) announced that the first subjects have been dosed in a Phase 1 trial evaluating SION-451,...

1M ago

SION

Sionna Therapeutics reports Q2 EPS (41c) vs ($2.71) last year

“We are pleased with the progress we’ve made this past quarter, underscored by the encouraging tolerability and PK...

2M ago

SION

Sionna Therapeutics Holds Annual Stockholders Meeting

Sionna Therapeutics, Inc. ( ($SION) ) has provided an update. On June 12, 2025, Sionna Therapeutics, Inc. held...

4M ago

SION

Sionna Therapeutics Reports Positive Phase 1 Trial Results

Sionna Therapeutics, Inc. ( ($SION) ) has provided an update. On June 4, 2025, Sionna Therapeutics announced positive...

4M ago

SION

Sionna Therapeutics announces data from Phase 1 trials of SION-719, SION-451

Sionna Therapeutics (SION) announced positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company’s...

4M ago

SION

Sionna Therapeutics reports Q1 EPS (62c), consensus (45c)

“Following our upsized IPO in February, we are in a strong financial position to advance our mission to...

5M ago

SION

Innovative Approach to Cystic Fibrosis Treatment: Sionna Therapeutics’ Pioneering Pipeline Earns Buy Rating

Sionna Therapeutics, Inc. (SION) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral. Ritu...

7M ago

SION

SION FAQ

What was Sionna Therapeutics, Inc.’s price range in the past 12 months?

Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $30.61 in the past 12 months.

What is Sionna Therapeutics, Inc.’s market cap?

Sionna Therapeutics, Inc.’s market cap is $1.26B.

When is Sionna Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Sionna Therapeutics, Inc.’s earnings last quarter?

Sionna Therapeutics, Inc. released its earnings results on May 12, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.448 by -$0.172.

Is Sionna Therapeutics, Inc. overvalued?

According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sionna Therapeutics, Inc. pay dividends?

Sionna Therapeutics, Inc. does not currently pay dividends.

What is Sionna Therapeutics, Inc.’s EPS estimate?

Sionna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sionna Therapeutics, Inc. have?

Sionna Therapeutics, Inc. has 44,139,824 shares outstanding.

What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?

Sionna Therapeutics, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.448. Following the earnings report the stock price went up 13.356%.

Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?

Currently, no hedge funds are holding shares in SION

Sionna Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

257.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Sionna Therapeutics, Inc. (SION) Earnings & Revenues

Historic Earnings Reports

SION Stock 12 Month Forecast

Average Price Target

$37.67

▲(28.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","28":"$28","47":"$47","18.5":"$18.5","37.5":"$37.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,18.5,28,37.5,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.39,26.975384615384616,28.560769230769232,30.146153846153847,31.731538461538463,33.316923076923075,34.902307692307694,36.487692307692306,38.073076923076925,39.65846153846154,41.24384615384616,42.82923076923077,44.41461538461539,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.39,26.334615384615386,27.27923076923077,28.223846153846154,29.16846153846154,30.113076923076925,31.05769230769231,32.002307692307696,32.94692307692308,33.89153846153846,34.83615384615385,35.78076923076923,36.72538461538462,{"y":37.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.39,25.12923076923077,24.86846153846154,24.607692307692307,24.346923076923076,24.086153846153845,23.825384615384614,23.564615384615387,23.303846153846155,23.043076923076924,22.782307692307693,22.521538461538462,22.26076923076923,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.24,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >